Hydrogenolysis of the benzyloxycarbonyl group in CBZ-D-phenylalaninol (molecular weight 285.34 g/mol) is the established front-end operation for chiral oxazolidinone auxiliary manufacture. The substrate is dissolved in methanol/tetrahydrofuran 70:30 v/v at a concentration of 0.8–1.2 mol/L. Palladium on activated carbon, 5% w/w, is charged at 2.0–5.0 wt% relative to substrate. Hydrogenation is conducted in a 50 L Hastelloy C-276 autoclave at 0.4–0.6 MPa hydrogen and 25–40°C for 4–8 h. Off-gas analysis indicates toluene and carbon dioxide liberation; incomplete venting of carbon dioxide can reduce catalyst activity. The slurry is filtered through a 0.5 µm sintered Hastelloy plate filter. After solvent swap to toluene, the free amine is cyclised with diethyl carbonate 1.5–2.0 equivalents in the presence of anhydrous potassium carbonate 0.05–0.10 equivalents at 110–135°C. Ethanol formed during cyclisation is removed by atmospheric distillation as a toluene azeotrope. The resulting (R)-4-benzyl-2-oxazolidinone is recrystallised from ethyl acetate/n-heptane 1:3 v/v. Residual palladium is controlled below 10 mg/kg by ICP-OES according to USP 233. Enantiomeric purity is measured by chiral GC on a Cyclosil-B 30 m × 0.25 mm column; the (S)-enantiomer limit is 0.5 area%. Published batch data for analogous D-phenylglycinol-derived oxazolidinones give isolated yields of 78–91% depending on carbonate selection; direct plant data for the Cbz-D-phenylalaninol substrate is limited. The terminal product is used as a chiral auxiliary in stereoselective aldol condensations.

How Does Competing O-Acylation Affect Peptide Alcohol Coupling Efficiency?

After hydrogenolytic removal of the Cbz group, D-phenylalaninol enters peptide alcohol assembly as an amino nucleophile. The primary hydroxyl is a competing nucleophile under standard carbodiimide activation. In a typical coupling, the activated peptide acid is generated with TBTU 1.05–1.10 equivalents and DIPEA 2.2–2.5 equivalents in dimethylformamide at -10°C to 0°C. D-Phenylalaninol is charged at 1.00 equivalent. Inverse addition of the preactivation solution to the amino alcohol suppresses O-acylated ester impurity. UPLC monitoring with a sub-2 µm C18 column shows the O-acylated side product is held below 0.5 area% when the internal temperature does not exceed 0°C during the first 30 min. Elevation to 10–15°C increases O-acylation to 2–5 area%, which is difficult to purge by aqueous workup. Process-grade dimethylformamide is dried to below 0.05% w/w water by Karl Fischer titration (USP 921) before use, because residual water hydrolyses the activated ester and shifts the required stoichiometry. Residual palladium from the upstream hydrogenolysis is controlled below 10 mg/kg to avoid precipitation with coordinating peptide residues. The terminal peptide alcohols are used in inhibitor structure-activity relationship libraries. Chiral purity is confirmed by HPLC on a Chiralpak AD-H 250 mm × 4.6 mm column, with the undesired enantiomer limited to 0.3 area%. Compliance with residual solvents is assessed by headspace GC according to USP 467, with methanol controlled below 3000 ppm and dimethylformamide below 880 ppm. Specific plant-scale batch data for this substrate are not publicly available.

A tridentate salicylaldimine ligand is prepared from CBZ-D-phenylalaninol after hydrogenolytic deprotection. The free amino alcohol is treated with 2.0–2.2 equivalents of 3,5-di-tert-butylsalicylaldehyde in methanol at 50–60°C for 1–2 h. The resulting Schiff base is reduced with sodium borohydride 1.1 equivalents at 0–5°C, yielding a tridentate N,O,O-ligand. Complexation with [RuCl₂(p-cymene)]₂ is performed at 0.5 molar equivalents relative to ligand in dichloromethane at 35–40°C for 4 h. The isolated Ru(II) complex is used in the asymmetric reduction of prochiral aryl ketones with formic acid/triethylamine as the hydrogen donor. Batch screening in 50 mL reactors evaluates substrate-to-catalyst ratios of 100:1 to 200:1. For substituted acetophenones, enantiomeric excesses of 90–95% are reported with the D-phenylalaninol-derived ligand when the aryl ketone carries an ortho electron-withdrawing group. Para-substituted substrates show lower selectivity. The terminal chiral alcohols are intermediates in cardiovascular and central nervous system active pharmaceutical ingredients. Process compliance includes palladium and ruthenium limits by ICP-MS according to USP 233, with ruthenium controlled below 10 mg/kg in isolated chiral alcohol. Few public datasets specify this exact ligand-substrate pair.

Conversion into N-Protected β-Amino Alcohols for HIV-1 Protease Inhibitor Isostere Synthesis

When the target is a hydroxyethylamine dipeptide isostere, CBZ-D-phenylalaninol is first oxidised to N-Cbz-D-phenylalaninal by Parikh-Doering oxidation. The substrate is charged in dichloromethane at 0.5–0.7 mol/L. Dimethyl sulfoxide is used at 3.0–3.2 equivalents, sulfur trioxide–pyridine complex at 3.0–3.5 equivalents, and triethylamine at 4.0–5.0 equivalents. The oxidation is maintained at -5°C to 5°C for 2–3 h, then quenched with 10% w/v citric acid. The aldehyde is used crude after cold solvent exchange. Grignard addition of isobutenylmagnesium bromide is run at 1.05–1.15 equivalents in tetrahydrofuran at -70°C to -60°C. Internal temperature excursions above -50°C reduce anti-selectivity and increase epimerised secondary alcohol. The product is a hydroxyethylamine dipeptide isostere intermediate for HIV-1 protease inhibitor scaffolds. Chiral purity is determined by HPLC on a Chiralpak AD-H 250 mm × 4.6 mm column; the syn diastereomer is limited to 2.0 area%. Residual tetrahydrofuran is controlled by headspace GC (USP 467) below 720 ppm. Pharmaceutical intermediate operations follow ICH Q3D elemental impurity risk assessment for palladium, chromium, and nickel. Comparative datasets for this precise building block configuration are scarce.

In chiral bisoxazoline ligand manufacture, D-phenylalaninol obtained by Cbz hydrogenolysis is condensed with pyridine-2,6-dicarbonitrile. The substrate ratio is 2.2 equivalents of amino alcohol to 1.0 equivalent of dinitrile. Zinc chloride at 0.10–0.20 equivalents is charged as a Lewis acid catalyst in chlorobenzene. The mixture is heated to 120–130°C for 12–20 h under a nitrogen sweep. Ammonia evolution is scrubbed into dilute sulfuric acid. The resulting (R,R)-2,6-bis(4-benzyl-4,5-dihydrooxazol-2-yl)pyridine is recovered by cooling to 0–5°C, filtration, and recrystallisation from acetonitrile. Chlorobenzene is controlled below 360 ppm in the isolated ligand according to ICH Q3C. Zinc is controlled below 25 mg/kg by ICP-OES. The terminal bisoxazoline ligand is used in copper-catalysed asymmetric cyclopropanation of styrene with ethyl diazoacetate. Catalyst batches require nitrogen atmosphere because the oxazoline ring undergoes slow hydrolysis at ambient relative humidity above 60%. Ligand chemical purity is monitored by chiral GC; process acceptance is typically above 99.0 area%. Open literature coverage for this exact chiral ligand is sparse.

When Aziridine Ring Closure Is Performed Under Water-Sensitive Conditions

Conversion of D-phenylalaninol to (R)-2-benzylaziridine requires sequential O-mesylation and intramolecular N-alkylation. The amino alcohol is dissolved in tetrahydrofuran at 0.2–0.5 mol/L. Methanesulfonyl chloride 1.05 equivalents is added over 60–90 min at -10°C to -5°C. Triethylamine 1.2–1.3 equivalents is charged concurrently to neutralise liberated hydrogen chloride. The mesylate intermediate is not isolated. After aqueous quench, the organic phase is dried to below 0.05% w/w water by Karl Fischer titration (USP 921). Cyclization is initiated by adding 30% w/w sodium hydroxide 2.5 equivalents at 20–25°C over 30 min. The exotherm is controlled with jacket coolant at 10–15°C. (R)-2-Benzylaziridine is recovered by fractional distillation under reduced pressure at 60–70°C and 1.0–2.0 kPa. The main process limit is water content, because residual water opens the aziridine to regenerate the amino alcohol during distillation. Mesylate ester content in the distilled product is limited to 0.1 area% by LC-MS. Storage is maintained at -20°C to -10°C under nitrogen. The terminal aziridine is used as a chiral electrophile in the synthesis of central nervous system active amine targets. Published pilot-plant data for this specific aziridine configuration are not available.